How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Jim Mueller, CFA, began his career as a scientist. He has five years of experience as a senior analyst and another four years as a research analyst. David Kindness is a Certified Public Accountant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results